| | ACS | | | Prevent The Event: Role of Oral Antiplatelet Therapy in the Management of the ACS Patient
Overview
The term acute coronary syndrome (ACS) is used to describe patients who present with either acute MI or unstable angina (UA). This program will provide an overview of ACS by discussing epidemiology, prevalance, acute and long term care treatment options as well as review current guidelines. Implementation of current treatment guidelines and patient adherence strategies in the primary care setting will also be discussed.
Objectives
Name 5 treatment recommendations for reduction of global CV risk in patients being medically managed for UA/NSTEMI
Describe 2 situations where dual antiplatelet therapy is recommended in patients with acute coronary syndrome
Faculty
Martin W. Schwarze, DO, FACC
Clinical Professor of Medicine
St. Louis University School of Medicine
St. Louis, MO
F. Wilford Germino, MD, FACP
Department of Internal Medicine
Orland Primary Care Specialists
Orland Park, IL
| | | Dyslipidemia | | | The Moving LDL Target: Getting Your Patients to Goal
Overview
The current use of lipid lowering therapy in clinical practice has fallen short of the recommendations of national guidelines. Clearly, not an easy venture when treating patients with dyslipidemia, many with multiple risk factors and many with resulting coronary events that may be preventable if patients were treated aggressively to meet the NCEP-ATP lll goals. This presentation will address the clinical challenges of goal attainment (lack of compliance, aggressive treatment by clinicians, not leaving patients 15 points from goals), and provide clinicians with the pathways and knowledge to help attain their patients to goal.
Objectives
Describe at least two challenges in treating dyslipidemia to NCEP-ATP III goals, implement strategies that will help to assess CHD risk accurately, and get patients to targeted goals
Identify patients at increased risk for cardiovascular events and develop a treatment plan with at least 2 lipid lowering strategies, including the use of multiple therapies, which will help these patients achieve guideline-based targets taking into consideration current lifestyle and pharmacologic treatment options available thus reducing overall cardiovascular risk
Faculty
Benjamin J. Ansell, MD
Assistant Professor of Internal Medicine
University of California, Los Angeles (UCLA) School of Medicine
Los Angeles, CA
Ronald A. Codario, MD, FACP
Clinical Instructor in Medicine
Thomas Jefferson University Hospital
Philadelphia, PA
| | | Insomnia | | | The Face of Insomnia: Risk-benefit Analyses and Pharmacologic Treatment of Insomnia
Overview
This course considers the growing complaint of insomnia in the primary care practice and offers practical approaches to diagnosis and treatment. With the immense importance of sleep, and the need to proactively address insomnia patients in the practice, this course will provide key steps to insomnia management leading to improved patient outcomes and overall health.
Objectives
Describe a patient-centered approach to the diagnosis of insomnia and development of a treatment plan
Apply the elements of a risk/benefit analysis for choosing a pharmacologic option to various patients at risk
Faculty
Rafael Pelayo, MD
Assistant Professor
Stanford University School of Medicine
Stanford, CA
Paul Doghramji, MD
| | | HPV | | | Reducing the Burden of HPV-Related Diseases: Cervical Cancer and Beyond
Overview
Human papillomavirus (HPV) is the most common newly acquired sexually transmitted infection in the United States. It is a necessary cause of cervical cancer and genital warts, and is associated with other anogenital and head and neck cancers, and recurrent respiratory papillomatosis. Prevention of HPV infection through prophylactic vaccination provides a safe and effective option to reduce the health burden associated with HPV-related diseases. Two vaccines have been developed: a quadrivalent HPV (6, 11, 16, 18) vaccine, approved by the US Food and Drug Administration (FDA), and a bivalent HPV (16, 18) vaccine, currently under FDA review. Both vaccines have demonstrated lasting efficacy against HPV-associated cervical disease and are generally well tolerated. This program will review the health consequences of HPV infection; provide an update on the safety and efficacy of HPV vaccines, including recent data on efficacy in mid-adult women, duration of protection, and cross-protection against nonvaccine HPV types; and evaluate the benefits of widespread HPV vaccination in preventing HPV-related diseases.
Objectives
Describe the epidemiology, natural history and consequences of HPV infection
Evaluate the anticipated benefits of widespread HPV vaccination in preventing cervical and anogenital cancers, genital warts, and other HPV-related diseases
Faculty
EJ Mayeaux, MD
Professor of Family Medicine
Professor of Obstetrics and Gynecology
Associate Family Practice Residency Program Director
Department of Family Medicine
Louisiana State University Health Sciences Center
School of Medicine
Shreveport, LA
Kenneth D. Hatch, MD
Professor of Obstetrics and Gynecology
Director, Female Pelvic Medicine and Reconstructive Surgery
University of Arizona College of Medicine
Tucson, Arizona
| | | Menstrual Migraine | | | A Practical Approach to Managing Menstrual Migraine: Tailoring Treatment and Individualizing Care
Overview
Migraine is a chronic, debilitating disorder that affects approximately 28 million Americans of whom ~18% are women and ~6% are men. When compared to migraines that occur during other times of the month, menstrual migraine (MM) may last longer and be more severe, disabling, frequent, and more difficult to treat. This program will address the new advances in the understanding of MM, the role of hormones, and how to select an appropriate treatment based on individual patient characteristics.
Objectives
Recognize migraine in the differential diagnosis of headaches that impact patients ability to fully function in their daily activities and identify menstrual migraine in female patients
Identify management strategies for women with menstrual migraine including use of headache calendars, behavioral modifications and approaches to acute and preventive treatment
Faculty
Susan L. Hutchinson, MD
Associate Clinical Professor, Department of Family Medicine
University of California, Irvine
Director, Orange County Migraine and Headache Center
Irvine, CA
Steven Graff-Radford, DDS
Director, Program for Headache and Orofacial Pain
The Pain Center, Cedars-Sinai Medical Center
Los Angeles, CA
| | | Zoster Virus | | | Preventing Herpes Zoster and Postherpetic Neuralgia: Are Your Patients Adequately Protected?
Overview
An estimated 1 million cases of herpes zoster (shingles) occur annually in the United States. The incidence and severity of herpes zoster increase with advancing age to produce substantial negative effects on quality of life, activities of daily living, neuropsychological functioning, and social status, resulting in significant morbidity in older adults. While antiviral therapy reduces the incidence and severity of herpes zoster, it does not reliably prevent postherpetic neuralgia (PHN), the most common and debilitating clinical sequela of herpes zoster. Herpes zoster vaccination has been demonstrated to reduce the incidence of the disease and its complications. Clinical trial data have demonstrated significant reductions in the incidence of herpes zoster and PHN, as well as overall reductions in the burden of disease.
Objectives
Review the epidemiology and public health burden of herpes zoster and its most common complication, postherpetic neuralgia (PHN)
Discuss the benefits and limitations of current pharmacotherapies for herpes zoster and Postherpetic neuralgia (PHN), and evaluate clinical trial data on the efficacy and safety of herpes zoster vaccination
Faculty
John F. Trowbridge, MD, CPE
Director, Chronic Conditions Management
Kaiser Permanente Santa Rosa
Clinical Professor of Medicine
University of California at San Francisco
San Francisco, CA
Stephen Allred, ANP
| | | Diabetes | | | Running a Winning Campaign Against Type 2 Diabetes: Evidence Based Therapeutic Decisions on Glycemic Control and Cardiovascular Risk
Overview
More than 20 million people are affected by diabetes and of this population nearly 65% will suffer early cardiovascular death. To effectively treat diabetes and reduce the risk of a cardiovascular event, glucose levels must be monitored and quickly controlled through changes in intervention, as outlined by the ADA/EASD treatment algorithm. Recent data provided by the National Health and Nutrition Examination Surveys (NHANES) revealed that there is some overall improvement in reaching the appropriate treatment standards, however, with the number of diabetes cases increasing by 1.5 million each year and the recent labeling changes affecting therapeutic options, it is more important than ever to be familiar with the pharmacologic treatment options for type 2 diabetes and the associated cardiovascular risk.
Objectives
Identify the current goals for A1C, blood pressure, and lipid levels set forth by the American Diabetes Association and apply them to the treatment strategies listed on the ADA/EASD algorithm in an effort to choose the best therapeutic option for each individual patient
Assess when patients with type 2 diabetes require cardiovascular risk reduction in addition to glycemic control and develop evidence-based approaches to treatment based on the ADA/EASD algorithm by reviewing adverse events
Faculty
Richard Pratley, MD
Professor of Medicine
Director, Diabetes and Metabolism
Translational Medicine Unit
University of Vermont College of Medicine
Burlington, VT
Mark Stolar, MD
Associate Professor of Clinical Medicine
Northwestern University
The Feinberg School of Medicine
Chicago, IL
| | | Chronic Constipation | | | Up-to-the-Second Advances in the Primary Care Management of Chronic Constipation and Other Functional Bowel Disorders
Overview
Chronic Constipation is a multi-symptom gastrointestinal motility disorder that negatively impacts the lives of approximately 33 million Americans. Due to the overlap in symptoms reported by patients with irritable bowel syndrome-constipation and chronic constipation, clinicians often find it challenging to differentiate between the two. With a changing landscape of therapeutic options available, it is imperative that clinicians be able to establish and accurate diagnosis so the proper foundation is provided for determining initial therapy and developing a treatment plan.
Objectives
Differentiate chronic constipation from other functional bowel disorders
Identify the therapies that can be used to treat chronic constipation and other functional bowel disorders
Faculty
Lin Chang, MD
Co-Director
Associate Professor of Medicine
Division of Digestive Diseases
Center for Neurovisceral Sciences & Women's Health
David Geffen School of Medicine UCLA
Los Angeles, CA
David A. Peura, MD, MACG, FACP
| | | Rhinitis | | | Allergic Rhinitis and Its Comorbidities: A Serious Challenge to the Healthcare Professional
Overview
Allergic rhinitis (AR) is the most common allergic condition in the US, affecting nearly 40 million people. Although AR is associated with significant comorbidities, current therapies have proven only modestly successful. Allergic Rhinitis and Its Comorbidities: A Serious Challenge to the Health Care Professional will provide primary care physicians with practical, evidence-based solutions to the challenges of managing AR, with particular emphasis on finding effective treatments and ensuring patient compliance. Two nationally recognized allergy/immunology experts will lead each 75-minute presentation with 60 minutes of didactic lectures and case history presentation, and a 15-minute question-and-answer session. Interactive discussion and a dynamic audience response system will also be integrated into the session.
Objectives
Describe key clinical characteristics of allergic rhinitis, its associated comorbidities, and its impact on patient health and quality of life
Identify barriers to treatment success of allergic rhinitis (treatment-related, physician-related, and patient-related barriers) and adequate control of symptoms, and devise strategies for overcoming those barriers
Faculty
Edwyn Boyd, MD
Clinical Assistant Professor, Dept. of Otolaryngology
University of Alabama at Birmingham
Hoover Ear, Nose, and Throat Associates
Hoover, AL
David H. Broide, MD
Professor of Medicine
Department of Medicine
Division of Allergy Immunology
University of California San Diego
San Diego, CA
| | | Eye Emergencies | | | Eye Emergencies Not to Miss in Primary Care
Overview
Eyesight is a gift that most patients take for granted, until their vision becomes acutely compromised. When that happens, patients often present first to their primary care clinician. Because of the lack of formal ophthalmology training, many primary care clinicians feel uncomfortable in managing patients with eye disease. This program will help primary care clinicians recognize eye emergencies by reviewing the signs and symptoms of 10 important conditions which may restore the patientŐs eyesight and perhaps save their life.
Objectives
Identify at least 2 eye emergencies that can cause rapid blindness or threaten life if not properly diagnosed in the primary care setting
Diagnose age-related macular degeneration, diabetic retinopathy, glaucoma, and optic nerve disease in the primary care setting and refer patients at risk to ophthalmology
Faculty
Tommy Korn, MD, FACS
Attending Ophthalmologist, Sharp Memorial Hospital
Sharp Rees-Stealy Medical Group
San Diego, CA
|
|
